Diroximel fumarate

Diroximel fumarate
Clinical data
Trade names	Vumerity
Other names	ALKS-8700
AHFS/Drugs.com	Monograph
MedlinePlus	a620002
License data	US DailyMed: Diroximel fumarate;
Pregnancy; category	AU: B3; ;
Routes of; administration	By mouth
ATC code	L04AX09 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Protein binding	Monomethyl fumarate (MMF): 27–45%
Metabolism	Esterases, citric acid cycle
Metabolites	MMF (active), hydroxyethyl succinimide (HES, inactive), CO2 (inactive)
Elimination half-life	1 hour
Excretion	MMF: 60% lung, 15.5% urine (?), 0.9% faeces; HES: 58–63% urine
Identifiers
CAS Number	1577222-14-0;
PubChem CID	73330464;
DrugBank	DB14783;
ChemSpider	57423290;
UNII	K0N0Z40J3W;
KEGG	D11154;
ChEMBL	ChEMBL3989944;
CompTox Dashboard (EPA)	DTXSID101026181 ;
Chemical and physical data
Formula	C11H13NO6
Molar mass	255.226 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC(=O)C=CC(=O)OCCN1C(=O)CCC1=O;
	InChI InChI=1S/C11H13NO6/c1-17-10(15)4-5-11(16)18-7-6-12-8(13)2-3-9(12)14/h4-5H,2-3,6-7H2,1H3/b5-4+; Key:YIMYDTCOUQIDMT-SNAWJCMRSA-N;

Diroximel fumarate, sold under the brand name Vumerity, is a medication used for the treatment of relapsing forms of multiple sclerosis (MS).^[3]^[5]^[6] It acts as an immunosuppressant and anti-inflammatory drug. Its most common adverse effects are flushing and gastrointestinal problems.^[7]

Diroximel fumarate was approved for medical use in the United States in October 2019,^[8] and in the European Union in November 2021.^[4]

^ ^a ^b "Vumerity APMDS". Therapeutic Goods Administration (TGA). 4 April 2022. Retrieved 24 April 2022.
^ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 21 December 2022. Retrieved 2 January 2023.
^ ^a ^b "Vumerity- diroximel fumarate capsule". DailyMed. Archived from the original on 5 February 2021. Retrieved 1 February 2021.
^ ^a ^b "Vumerity EPAR". European Medicines Agency. 14 September 2021. Archived from the original on 25 November 2021. Retrieved 24 November 2021.
^ Wang Y, Bhargava P (July 2020). "Diroximel fumarate to treat multiple sclerosis". Drugs of Today. 56 (7): 431–437. doi:10.1358/dot.2020.56.7.3151521. PMID 32648853. S2CID 220471534.
^ Kourakis S, Timpani CA, de Haan JB, Gueven N, Fischer D, Rybalka E (October 2020). "Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?". Pharmaceuticals (Basel, Switzerland). 13 (10): 306. doi:10.3390/ph13100306. PMC 7602023. PMID 33066228.
^ Cite error: The named reference AC was invoked but never defined (see the help page).
^ "Drug Approval Package: Vumerity". U.S. Food and Drug Administration (FDA). 21 April 2020. Archived from the original on 6 February 2021. Retrieved 1 February 2021.